David Gardner

Ventas & Marketing en

iShares Plc

Finance

Miscellaneous

Health Technology

Perfil

David Gardner is currently the Head-EMEA Sales at iShares Plc.
Prior to this, he worked as a Director at Xilio Therapeutics, Inc. in 2021.
He also worked as an Analyst at BlackRock Advisors LLC from 2009 to 2011.

Cargos activos de David Gardner

Empresas	Cargo	Inicio
iShares Plc iShares Plc Investment Trusts/Mutual FundsMiscellaneous Exchange Traded Fund	Ventas & Marketing	20/10/2011

Todos los cargos activos de David Gardner

Antiguos cargos conocidos de David Gardner.

Empresas	Cargo	Fin
XILIO THERAPEUTICS, INC.	Director/Miembro de la Junta	01/10/2021
BlackRock Advisors LLC BlackRock Advisors LLC Investment ManagersFinance BlackRock Advisors offers investors around the world a variety of investment products that span across asset classes, market-caps, investment styles and geographic regions. Their mandates include cash management, equity, fixed income, alternative, multi-asset and quantitative equity strategies.	Analyst-Equity	09/09/2011

Ver el detalle de la experiencia de David Gardner.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de David Gardner.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	3
BlackRock Advisors LLC BlackRock Advisors LLC Investment ManagersFinance BlackRock Advisors offers investors around the world a variety of investment products that span across asset classes, market-caps, investment styles and geographic regions. Their mandates include cash management, equity, fixed income, alternative, multi-asset and quantitative equity strategies.	Finance
iShares Plc iShares Plc Investment Trusts/Mutual FundsMiscellaneous Exchange Traded Fund	Miscellaneous
Xilio Therapeutics, Inc. Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies	Health Technology